These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37753033)

  • 1. Assessing the Compliance of Physicians With the American Diabetes Association (ADA) Guidelines in Prescribing Cardioprotective Antihyperglycemic Agents to Diabetic Patients at a University Hospital in Jeddah, Saudi Arabia.
    Sheikh AM; Sheikh A; Alhozali A; Alshaikhi SA
    Cureus; 2023 Aug; 15(8):e44133. PubMed ID: 37753033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
    Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
    J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
    Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
    Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence of physicians to evidence-based management guidelines for treating type 2 diabetes and atherosclerotic cardiovascular disease in Ajman, United Arab Emirates.
    Alliabi FJA; Jaber AAS; Jallo MKI; Baig MR
    BMC Prim Care; 2022 Apr; 23(1):70. PubMed ID: 35392814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia.
    Alshaya OA; Korayem GB; Alghwainm M; Alyami W; Alotaibi A; Alyami MS; Almohammed OA
    Saudi Pharm J; 2024 May; 32(5):102054. PubMed ID: 38590611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing pattern of anti-diabetic drugs and adherence to the American Diabetes Association's (ADA) 2021 treatment guidelines among patients of type 2 diabetes mellitus: A cross-sectional study.
    Tiwari K; Bisht M; Kant R; Handu SS
    J Family Med Prim Care; 2022 Oct; 11(10):6159-6164. PubMed ID: 36618206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicians' perceptions and beliefs on the current dyslipidemia management practices within Saudi Arabia.
    Almigbal TH; Almunif DS; Ali Deshisha E; Altaradi H; Alrasheed AA; Batais MA; Alhabib KF
    Saudi Pharm J; 2023 Oct; 31(10):101759. PubMed ID: 37705879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.
    Lin SN; Phang KK; Toh SH; Chee KH; Zaman Huri H
    Front Endocrinol (Lausanne); 2020; 11():448. PubMed ID: 32754118
    [No Abstract]   [Full Text] [Related]  

  • 13. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure.
    Lopez PD; Bhatia K; Bohra C; Mahmood K; Baruch L; Eng C
    Am J Cardiol; 2022 Oct; 181():87-93. PubMed ID: 35963825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Practices and Gaps in Management of Dyslipidemia in Type 2 Diabetes Mellitus (T2DM) in Accordance with American Diabetes Association (ADA) Guidelines: A Subset Analysis from a Real-World, Cross-Sectional Observational Study (LEADD Study).
    Das AK; Saboo B; Unnikrishnan AG
    Diabetes Metab Syndr Obes; 2021; 14():2693-2700. PubMed ID: 34163197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of risk factors for cardiovascular diseases among Saudi diabetic patients attending primary health care service.
    Ahmed AA; Alsharief E; Alsharief A
    Diabetes Metab Syndr; 2013; 7(3):133-7. PubMed ID: 23953177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.
    Ferraro RA; Nass CM; Dudum R; Blumenthal RS; Sarkar S
    Am J Med; 2019 Sep; 132(9):1027-1031. PubMed ID: 30904510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events.
    Towiargi R; Fetyani L; Aljahdali N; Alnofeie A; Alnoamy Y; Ghandorah R; Abduljawad A; Alharbi N; Alghanmi A; AlButi H
    Cureus; 2022 Dec; 14(12):e33070. PubMed ID: 36721538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.